Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NaPro/Ivax Paxene

Executive Summary

Companies terminate paclitaxel development and marketing agreement. Ivax will return its 1.1 mil. shares of NaPro stock and pay $6 mil. in exchange for a royalty-free, non-exclusive license to NaPro's pending paclitaxel patents. Ivax will also make additional payments of up to $6.4 mil. upon issuance of a patent. NaPro will continue to supply Ivax with paclitaxel while Ivax finds a new supplier, and NaPro is seeking a new marketing partner. An NDA for Paxene use in Kaposi's sarcoma is blocked until 2004 by Bristol's orphan exclusivity for Taxol
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS031909

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel